What is malignant struma ovarii?
Malignant struma ovarii is a rare cancer of the ovary made of thyroid tissue. It sounds surprising, but the ovary can occasionally contain tissue that looks and works like the thyroid gland in the neck. This happens within a type of teratoma, a germ cell tumour that can produce many different kinds of body tissue.
When a teratoma consists mostly of thyroid tissue, it is called struma ovarii. Struma ovarii itself is uncommon, accounting for about 0.3-1% of ovarian tumours, and most are benign (Addley et al., 2021). In a small proportion, the thyroid tissue develops into thyroid-type cancer, most often papillary thyroid carcinoma. This is called malignant struma ovarii.
The condition usually affects women in their 30s and 40s. It is rarely suspected before surgery, because it looks like other ovarian masses on scans. The diagnosis is normally made when the pathologist examines the removed ovary.
The outlook is generally excellent. Many women need only surgery to remove the affected ovary. Thyroid-directed treatment, such as removal of the thyroid gland followed by radioactive iodine, is used for women at higher risk or with spread. A recent pooled analysis found that about 9 in 10 women were alive 10 years after surgery (Jenkins et al., 2025).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Thyroid-type carcinoma arising in struma ovarii (an ovarian teratoma) |
| How common | Very rare; struma ovarii is 0.3-1% of ovarian tumours, and only a minority are malignant |
| Typical age | Mean about 43-44 years |
| Most common type | Papillary thyroid carcinoma |
| Diagnosis before surgery | Rarely made |
| Main treatment | Surgery; thyroidectomy and radioactive iodine for selected women |
| Tumour marker | Thyroglobulin in the blood for follow-up |
| Spread | Mainly within the pelvis and abdomen |
| Outlook | Excellent; about 91% alive at 10 years in pooled data |
2. Types
Types of thyroid cancer found in struma ovarii
In an analysis of 144 published patients, the following types were found (Cui et al., 2021):
| Type | Share |
|---|---|
| Papillary thyroid carcinoma | About 50% |
| Follicular thyroid carcinoma | About 26% |
| Follicular variant of papillary carcinoma | About 19% |
| Mixed papillary and follicular | About 3% |
| Anaplastic or medullary carcinoma | Under 1% each |
Highly differentiated follicular carcinoma of ovarian origin
Some tumours look almost like normal thyroid tissue but still spread to the peritoneum. This form, once called “peritoneal strumosis”, is now recognised as a very well-differentiated cancer that usually grows slowly.
Pure and impure forms
| Form | Description |
|---|---|
| Pure | The tumour consists of thyroid tissue only |
| Impure (mixed) | Thyroid tissue mixed with other teratoma elements, such as skin or fat |
About 70% of cases in the pooled series were of the impure type (Cui et al., 2021).
Related ovarian tumours
| Tumour | How it differs |
|---|---|
| Benign struma ovarii | Thyroid tissue without cancer |
| Strumal carcinoid | Thyroid tissue mixed with a neuroendocrine tumour |
| Mature cystic teratoma (dermoid cyst) | Contains many tissue types; usually benign |
| Metastatic thyroid cancer | Spread from the thyroid gland to the ovary; very rare |
3. Causes and risk factors
The cause is not known.
| Factor | Notes |
|---|---|
| Ovarian teratoma | The tumour arises within thyroid tissue of a teratoma |
| Age | Usually adult women of reproductive age |
| Gene changes in the tumour | Changes in BRAF, NRAS, KRAS and KIT similar to thyroid cancer; some tumours have none |
| Inherited factors | No clear link |
About a third of tumours tested in the pooled series had no detectable gene change (Cui et al., 2021).
4. How does it look
On scans
| Test | Typical findings |
|---|---|
| Pelvic ultrasound | Mixed solid and cystic mass of one ovary |
| CT or MRI | Multi-compartment cyst with solid areas; may show fat or calcium from teratoma elements |
| Iodine scan after surgery | Shows whether remaining tumour takes up iodine |
None of these findings is specific, and in one centre’s series no case was correctly identified before surgery (Addley et al., 2021).
Under the microscope
| Feature | Description |
|---|---|
| Thyroid follicles | Round sacs filled with colloid, just like the thyroid gland |
| Papillary carcinoma features | Clear, overlapping nuclei with grooves and inclusions |
| Follicular carcinoma features | Invasion of capsule or blood vessels |
| Stains | Thyroglobulin and TTF-1 positive |
Blood tests
| Test | Notes |
|---|---|
| CA125 | Raised in about half of patients tested; not specific |
| Thyroglobulin | Useful marker for monitoring after treatment |
| Thyroid function | Usually normal; overactive thyroid occurs occasionally |
Why it is rarely diagnosed before surgery
Ovarian masses are common, and most are benign cysts. Malignant struma ovarii has no typical scan appearance and no specific blood test, so it is almost always discovered unexpectedly when the removed ovary is examined. In the pooled analysis of 144 women, about one in six cases was initially misdiagnosed (Cui et al., 2021). Pathologists must look carefully for small areas of cancer within otherwise normal-looking thyroid tissue, because these can be easily missed.
When the diagnosis is made after surgery, a second planning meeting usually follows. The team then decides whether any further treatment is needed, which may include imaging, blood tests and an assessment of the neck thyroid.
5. Symptoms
Many women have symptoms from the ovarian mass itself. In pooled case reports, about four in five were symptomatic (Jenkins et al., 2025).
Common symptoms
- Pelvic or lower abdominal pain
- A swollen or bloated abdomen
- A lump felt in the lower abdomen
- Changes in periods
Less common symptoms
| Symptom | Possible cause |
|---|---|
| Fluid in the abdomen (ascites) | Spread to the peritoneum or a reaction to the tumour |
| Fluid around the lungs | Rarely, as part of a syndrome with ovarian tumours |
| Weight loss, palpitations, heat intolerance | Overactive thyroid from hormone production (rare) |
| Sudden severe pain | Twisting (torsion) of the ovary |
| Bone pain or cough | Distant spread (rare) |
When to seek medical advice
See your doctor about persistent bloating, pelvic pain, feeling full quickly or a change in bowel or bladder habit, especially if these happen most days for several weeks.
6. Diagnosis
| Step | Purpose |
|---|---|
| Pelvic ultrasound | First test for an ovarian mass |
| CA125 and other markers | Assess the likelihood of cancer |
| CT or MRI | Describe the mass and check for spread |
| Surgery | Removes the ovary; provides the diagnosis |
| Pathology review | Confirms thyroid-type carcinoma and its features |
| Thyroid examination and ultrasound | Excludes a cancer in the neck thyroid |
| Thyroglobulin blood test | Baseline for follow-up |
Risk assessment after surgery
| Lower risk | Higher risk |
|---|---|
| Small cancer confined to the struma | Large tumour |
| Stage I disease | Spread beyond the ovary |
| No aggressive features | Aggressive histology or vascular invasion |
| Normal thyroglobulin after surgery | Raised thyroglobulin after surgery |
7. Treatment
There are no clinical trials, and practice varies. Experts recommend multidisciplinary team care, combining gynaecological oncology, endocrinology and nuclear medicine (Addley et al., 2021).
Surgery
| Situation | Typical operation |
|---|---|
| Stage I, wishes to keep fertility | Removal of the affected ovary and tube (unilateral salpingo-oophorectomy) |
| Stage I, family complete | Removal of the ovary; more extensive surgery may be discussed |
| Spread within the abdomen | Removal of both ovaries, womb, omentum and visible deposits |
For stage I disease, removal of the affected ovary alone may be adequate, with more radical surgery reserved for advanced cases (Addley et al., 2021).
Thyroid-directed therapy
| Treatment | Purpose |
|---|---|
| Total thyroidectomy | Removes the neck thyroid so radioactive iodine goes to remaining tumour cells, and checks for a separate thyroid cancer |
| Radioactive iodine (I-131) | Destroys remaining thyroid-type cancer cells |
| Thyroid hormone (levothyroxine) suppression | Lowers TSH, which can stimulate cancer growth |
These treatments are generally recommended when there is spread and the tumour takes up iodine (Cui et al., 2021).
The debate about thyroid treatment
A meta-analysis of 376 patients found that survival was not clearly improved by thyroidectomy, radioactive iodine or thyroid hormone therapy. The authors suggested that thyroid-directed treatment may sometimes be overtreatment (Jenkins et al., 2025). Many specialists now use these treatments selectively, based on the risk features of each case.
Treatment by situation
| Situation | Typical approach |
|---|---|
| Small, low-risk cancer confined to the ovary | Surgery, then thyroglobulin monitoring |
| Higher-risk features but no spread | Surgery; thyroidectomy and radioactive iodine considered |
| Spread in the abdomen | Debulking surgery, thyroidectomy, radioactive iodine |
| Recurrence | Surgery, further radioactive iodine or other treatments |
Side effects
| Treatment | Possible side effects |
|---|---|
| Ovarian surgery | Pain, wound problems; early menopause if both ovaries are removed |
| Thyroidectomy | Hoarse voice, low calcium, lifelong thyroid hormone tablets |
| Radioactive iodine | Dry mouth, altered taste, temporary isolation precautions |
| Thyroid hormone suppression | Palpitations, bone thinning if the dose is high |
Fertility and pregnancy
Because many women are young, fertility-sparing surgery is often possible. After radioactive iodine, women are usually advised to avoid pregnancy for 6-12 months.
8. Outlook (prognosis)
| Measure | Result |
|---|---|
| Overall survival at 10 years (pooled) | About 91% |
| Overall survival at 20 years (pooled) | About 87% |
| Recurrence in case reports | About 27%, at a median of 4 years |
These figures come from Jenkins et al. (2025). In the pooled analysis by Cui and colleagues, death was linked with spread and with the type of cancer, but survival was high overall. In the Oxford series of 11 women, all had stage I disease and none had a recurrence (Addley et al., 2021).
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Thyroglobulin blood tests | Rising levels suggest recurrence |
| Pelvic ultrasound or CT | Checks the pelvis and abdomen |
| Neck ultrasound | If the thyroid was not removed |
| Thyroid function tests | For women on thyroid hormone |
| Long-term review | Recurrence can occur many years later |
Thyroglobulin is most reliable as a marker after the neck thyroid has been removed. A case report also showed its use in monitoring a woman treated with surgery and thyroid hormone alone (Yassa, Sadow and Marqusee, 2008).
10. Living with malignant struma ovarii
- Take thyroid hormone tablets consistently, if prescribed, and have regular blood tests
- Plan pregnancies with your team, especially after radioactive iodine
- Discuss menopause symptoms if both ovaries were removed; hormone replacement may be possible
- Keep follow-up appointments, as recurrence can be late
- Look after bone health with exercise, calcium and vitamin D
- Carry a list of your treatments, including any radioactive iodine dates
- Seek support from ovarian and thyroid cancer charities
11. Frequently asked questions
| Question | Answer |
|---|---|
| How can thyroid cancer grow in the ovary? | Teratomas can produce thyroid tissue, which can turn cancerous |
| Is it ovarian cancer or thyroid cancer? | It is a thyroid-type cancer arising in the ovary |
| Do I need my thyroid removed? | Not always; it depends on the risk features and spread |
| Can I still have children? | Often yes, if the other ovary and womb are kept |
| Is the outlook good? | Generally excellent |
| Can it come back? | Yes, sometimes years later, so follow-up continues |
| Is it inherited? | No clear inherited link is known |
| Will I need to be isolated after radioactive iodine? | For a few days, to protect others from radiation; your team will give precise advice |
12. Questions to ask your care team
- What type of thyroid cancer was found, and what stage is it?
- Is my case low or high risk?
- Do I need thyroidectomy or radioactive iodine?
- Can my fertility be preserved?
- How will thyroglobulin be used in my follow-up?
- Who will coordinate my care between gynaecology and endocrinology?
- Should my neck thyroid be checked with an ultrasound?
- What symptoms should prompt me to get in touch before my next appointment?
Resources
- Addley, S. et al. (2021) ‘Malignant struma ovarii: surgical, histopathological and survival outcomes for thyroid-type carcinoma of struma ovarii with recommendations for standardising multi-modal management. A retrospective case series sharing the experience of a single institution over 10 years’, Archives of Gynecology and Obstetrics, 303(4), pp. 863-870.
- Cui, Y. et al. (2021) ‘The clinical and pathological characteristics of malignant struma ovarii: an analysis of 144 published patients’, Frontiers in Oncology, 11, 645156.
- Jenkins, C.R. et al. (2025) ‘Prognostic significance of surgically treated malignant struma ovarii with or without adjuvant thyroid-related therapy: a systematic review and meta-analysis’, World Journal of Surgery, 49(2), pp. 401-408.
- Yassa, L., Sadow, P. and Marqusee, E. (2008) ‘Malignant struma ovarii’, Nature Clinical Practice Endocrinology and Metabolism, 4(8), pp. 469-472.
- National Cancer Institute (2026) Ovarian Germ Cell Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-germ-cell-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.